CA2525615A1 - Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine - Google Patents
Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine Download PDFInfo
- Publication number
- CA2525615A1 CA2525615A1 CA002525615A CA2525615A CA2525615A1 CA 2525615 A1 CA2525615 A1 CA 2525615A1 CA 002525615 A CA002525615 A CA 002525615A CA 2525615 A CA2525615 A CA 2525615A CA 2525615 A1 CA2525615 A1 CA 2525615A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- vaccine composition
- iron phosphate
- phosphate
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 10
- 229910000398 iron phosphate Inorganic materials 0.000 title claims abstract 6
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 title claims abstract 6
- 229960005486 vaccine Drugs 0.000 title claims 11
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title abstract 2
- 239000002245 particle Substances 0.000 claims abstract 4
- 150000002505 iron Chemical class 0.000 claims abstract 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 2
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000012266 salt solution Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to vaccination compositions comprising iron phosphate as a pharmaceutical aid. Said iron phosphate is present in the form of particles whose size ranges from 0.01~m and 300~m; it can be obtained by mixing an iron salt and phosphate salt solution.
Claims (8)
1. A vaccine composition comprising at least one vaccine antigen and at least one adjuvant, characterized in that the adjuvant comprises iron phosphate.
2. The vaccine composition as claimed in the preceding claim, characterized in that the iron phosphate is present in the form of a suspension of particles, the size of which is between 0.01 µm and 300 µm.
3. The vaccine composition as claimed in the preceding claim, characterized in that the size of the particles is between 1 and 40 µm.
4. The vaccine composition as claimed in one of the preceding claims, characterized in that the size of the particles is centered around a value of 7 µm.
5. The vaccine composition as claimed in one of the preceding claims, characterized in that the iron phosphate is prepared from a solution of iron salt and of phosphate salt.
6. The vaccine composition as claimed in one of the preceding claims, characterized in that it comprises at least the tetanus antigen.
7. The vaccine composition as claimed in one of the preceding claims, characterized in that it comprises at least the diphtheria antigen.
8. The vaccine composition as claimed in one of the preceding claims, characterized in that it comprises at least one poliomyelitis antigen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR03/05876 | 2003-05-16 | ||
| FR0305876A FR2854803B1 (en) | 2003-05-16 | 2003-05-16 | VACCINE COMPOSITION COMPRISING IRON PHOSPHATE AS VACCINE. |
| PCT/FR2004/001175 WO2004103408A2 (en) | 2003-05-16 | 2004-05-14 | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2525615A1 true CA2525615A1 (en) | 2004-12-02 |
| CA2525615C CA2525615C (en) | 2012-03-13 |
Family
ID=33306396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2525615A Expired - Fee Related CA2525615C (en) | 2003-05-16 | 2004-05-14 | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1628683B1 (en) |
| JP (1) | JP4711964B2 (en) |
| CN (1) | CN100384476C (en) |
| AT (1) | ATE430582T1 (en) |
| CA (1) | CA2525615C (en) |
| DE (1) | DE602004020985D1 (en) |
| FR (1) | FR2854803B1 (en) |
| WO (1) | WO2004103408A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571925A (en) * | 2018-03-08 | 2019-09-18 | Univ Antwerpen | Iron-based vaccine adjuvants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE565793A (en) * | 1957-03-19 | 1900-01-01 | ||
| DE3834729A1 (en) * | 1988-10-12 | 1990-04-19 | Behringwerke Ag | USE OF ZINC OR IRON HYDROXIDE FOR ADJUVATING ANTIGEN SOLUTIONS AND ANY ADJUSTED ANTIGEN SOLUTIONS THEREFOR |
| DE19511276C2 (en) * | 1995-03-27 | 1999-02-18 | Immuno Ag | Adjuvant based on colloidal iron compounds |
| DE69935606T9 (en) * | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | ADJUVANCE SYSTEMS AND VACCINE |
| GB0025058D0 (en) * | 2000-10-12 | 2000-11-29 | Smithkline Beecham Biolog | Composition |
| RU2323002C2 (en) * | 2001-07-26 | 2008-04-27 | Чирон Срл. | Vaccines comprising aluminum adjuvants and histidine |
-
2003
- 2003-05-16 FR FR0305876A patent/FR2854803B1/en not_active Expired - Fee Related
-
2004
- 2004-05-14 DE DE602004020985T patent/DE602004020985D1/en not_active Expired - Lifetime
- 2004-05-14 JP JP2006530351A patent/JP4711964B2/en not_active Expired - Fee Related
- 2004-05-14 WO PCT/FR2004/001175 patent/WO2004103408A2/en active Application Filing
- 2004-05-14 AT AT04742725T patent/ATE430582T1/en not_active IP Right Cessation
- 2004-05-14 CA CA2525615A patent/CA2525615C/en not_active Expired - Fee Related
- 2004-05-14 CN CNB2004800133652A patent/CN100384476C/en not_active Expired - Fee Related
- 2004-05-14 EP EP04742725A patent/EP1628683B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN100384476C (en) | 2008-04-30 |
| ATE430582T1 (en) | 2009-05-15 |
| FR2854803A1 (en) | 2004-11-19 |
| WO2004103408A2 (en) | 2004-12-02 |
| JP4711964B2 (en) | 2011-06-29 |
| WO2004103408A3 (en) | 2005-03-17 |
| EP1628683B1 (en) | 2009-05-06 |
| DE602004020985D1 (en) | 2009-06-18 |
| CA2525615C (en) | 2012-03-13 |
| CN1791432A (en) | 2006-06-21 |
| JP2006528958A (en) | 2006-12-28 |
| EP1628683A2 (en) | 2006-03-01 |
| FR2854803B1 (en) | 2005-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004110480A3 (en) | Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines | |
| WO2001093829A3 (en) | Powder compositions | |
| WO2006037787A3 (en) | Vlp-antigen conjugates and their uses as vaccines | |
| EP2258384A3 (en) | Neisseria vaccine composition | |
| WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
| IL173885A (en) | Ethyl-3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1- methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate in crystalline form ii, pharmaceutical composition comprising it and uses thereof for preparing pharmaceutical compositions which are suitable for the post-operative prophylaxis of deep vein thrombosis and the prevention of stroke and process for the preparation thereof | |
| EP2348036A3 (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease | |
| EP2246067A3 (en) | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes | |
| WO2006038908A3 (en) | Ancestral and cot viral sequences, proteins and immunogenic compositions | |
| AUPR011700A0 (en) | Composition comprising immunogenic virus sized particles (VSP) | |
| EP2601969A3 (en) | Norovirus vaccine formulations | |
| WO2004033663A3 (en) | Carbohydrate-based synthetic vaccines for hiv | |
| WO2003039459A3 (en) | Viral vector production methods and compositions | |
| BRPI0511574A (en) | composition, method of depositing a sugar polyester on a substrate, and use of a composition | |
| WO2008012399A3 (en) | Novel compositions of fungal inocula, method for the preparation thereof and use thereof for improving the growth of cultures | |
| AU2002221519A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
| WO2008008541A8 (en) | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes | |
| MX2007009961A (en) | Adjuvant composition comprising aluminium phosphate and 3d-mpl. | |
| CA2525615A1 (en) | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine | |
| WO2005021726A3 (en) | Immunogenic hiv compositions and related methods | |
| WO2006030301A8 (en) | Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers | |
| WO2023235660A3 (en) | Flavivirus immunogens and vaccine compositions and methods of using the same | |
| WO2007031334A3 (en) | Vaccines comprising truncated hbc core protein plus saponin-based adjuvants | |
| EP2757197A3 (en) | Retroreflective elements and articles | |
| EP2347764A3 (en) | Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170515 |